Download the Visual
Manufacturing readiness, not novel science, gates China biotech partnerships
Few China-developed Phase 2 and Phase 3 assets were ready for a US or EU partnership, and the biggest barriers were sponsor experience and manufacturing readiness. Sleuth’s January 2026 funnel found that only 12 of 412 such assets, about 3%, met every execution requirement: no existing global partner, a sponsor with prior cross-border deal experience, an advanced clinical stage and manufacturing readiness. BD teams hunting for breakthrough science, novel targets and pristine IP are asking the wrong question, because chemistry, manufacturing and controls (CMC) transferability, not clinical differentiation, is the rate-limiting step.
Four filters cut 412 assets to 12
Sleuth scored the 412 assets on clinical, IP, CMC and geopolitical dimensions. Removing the 48 that already had global partners (12%) leaves 364 available for new US or EU deals. Requiring a sponsor with at least one prior cross-border deal removes 239 more (66% of that pool), leaving 125. Limiting those to Phase 3 or near-term pivotal readouts leaves 28, and requiring commercial-scale manufacturing or US/EU GMP compliance leaves 12.
Sponsor track record is the largest single cut, and it matters for price. In Sleuth’s historical deal analysis, sponsors with five or more prior cross-border transactions commanded median upfront payments of about $60 million for Phase 2 assets, yet only about a third of the unpartnered assets (125 of 364) come from sponsors with any cross-border deal experience.
A buyer with a mandate to close a Phase 2 or Phase 3 China deal in 2025 or 2026 is choosing from about a dozen partnership-ready candidates, and only 28 even before manufacturing is screened.
The assets that clear the bar are operationally ready, not cutting-edge
In Sleuth’s analysis, the assets that pass are mostly biosimilar anti-PD-1 antibodies, follow-on ADCs and reformulated small molecules from sponsors such as Hengrui, Bio-Thera and CSPC. These sponsors have transferred manufacturing before, maintain dual China and Western compliance and can assemble FDA CMC packages without starting from scratch.
Dozens of more innovative programs, including novel immuno-oncology combinations, differentiated cell therapies and first-in-class small molecules, remain stuck at clinical supply scale with China-only GMP and no experience transferring to a Western contract manufacturer. Sleuth estimates that tech transfer alone adds 18 to 24 months, on top of the 6 to 9 months that geopolitical uncertainty already adds to diligence, which effectively rules them out of a near-term deal.
The candidates a buyer can close on soon are mostly clinically undifferentiated but operationally de-risked.
What Sleuth expected for China partnering from 2026
These are Sleuth’s views as of January 2026. The breakthrough science BD teams want is either already partnered or will not be ready for US or EU tech transfer until 2027 or later, so assets with 2025 or 2026 readouts, experienced sponsors and manufacturing infrastructure will command premiums despite unremarkable science. For Chinese biotech executives, Western GMP compliance, commercial-scale manufacturing and proven tech transfer need to be in place before Phase 2 topline data; otherwise an asset competes with the 400 in this funnel that fail at least one filter.
Since this analysis, Sleuth’s April 2026 China biopharma landscape found that Western buyers were licensing Chinese assets earlier and taking on FDA evidence generation and manufacturing upgrades themselves.
Asset counts and estimates come from Sleuth’s analysis published in January 2026, and this page is a dated snapshot. The later buyer-behavior finding comes from Sleuth’s April 2026 China biopharma landscape.
Frequently asked questions about China biotech partnerships
How many China-developed Phase 2/3 assets are ready for a US or EU partnership?
In Sleuth’s January 2026 analysis, 12 of 412 China-developed Phase 2 and 3 assets, about 3%, cleared all four filters: no global partner, an experienced sponsor, Phase 3 or near-term pivotal readouts, and commercial-scale manufacturing or US/EU GMP compliance.
What is the biggest barrier to partnering Chinese biotech assets in the US or EU?
Sponsor experience and manufacturing readiness. In Sleuth’s January 2026 funnel, requiring a sponsor with a prior cross-border deal removed 239 of 364 unpartnered assets, and manufacturing readiness removed 16 of the last 28. Sleuth estimated that tech transfer for assets with China-only GMP adds 18 to 24 months.
Which Chinese companies have partnership-ready assets?
Sleuth’s January 2026 analysis points to experienced sponsors such as Hengrui, Bio-Thera and CSPC, whose passing assets are mostly biosimilar anti-PD-1 antibodies, follow-on ADCs and reformulated small molecules.
